The Great News – Lifestyle
Home
Sample Page
Author:
Relay Therapeutics, Inc.
Relay Therapeutics Announces Proposed Public Offering of Common Stock
May 19, 2026
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
May 19, 2026
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
May 5, 2026
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
April 30, 2026
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
April 29, 2026
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
April 2, 2026
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
March 16, 2026